For laboratory and research use only. The following content is provided for scientific and educational purposes. Struck Bio Labs compounds are not intended for human consumption, injection, or clinical use and have not been evaluated by the Food and Drug Administration. This content does not constitute medical advice. See our full disclaimer at struckbiolabs.com/disclaimer/.
GHK-Cu — the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine — occupies an unusual position in peptide research: it is an endogenous molecule, identified first in human plasma, that has subsequently been characterized through decades of published cell-culture and animal studies for its effects on extracellular matrix biology, wound-repair signaling, and gene expression modulation. Its research history is anchored in the work of Loren Pickart, who isolated GHK from human plasma albumin as early as 1973 and spent subsequent decades characterizing its biological activity. The copper-binding capacity of the His residue at position two confers on the tripeptide a distinct coordination chemistry that appears integral to its biological effects, distinguishing GHK-Cu from GHK alone. The body of published literature on this molecule spans collagen biochemistry, fibroblast culture models, wound-healing animal studies, and, more recently, genomic analyses that identify GHK-Cu as a broad gene expression modulator — making it a research compound of continuing interest across multiple laboratory disciplines.
What Is GHK-Cu Peptide?
GHK-Cu is the copper(II) chelate of the tripeptide H-Gly-His-Lys-OH. The sequence Gly-His-Lys was originally identified by Pickart as a fragment present in the alpha-2-macroglobulin fraction of human plasma albumin, where it appeared in tissue-regeneration contexts. The histidine residue provides the primary coordination site for Cu²⁺ through its imidazole nitrogen, while the terminal lysine amine and the glycine alpha-amino group participate in square-planar copper coordination geometry. Endogenous plasma concentrations of GHK have been reported at approximately 200 ng/mL in younger adults, with levels declining with age — an observation that has framed much of the interest in GHK-Cu as a research subject in aging biology. The molecule’s small size (molecular weight approximately 340 Da for the free tripeptide) and high water solubility facilitate uptake into cell culture systems, and its picomolar-to-nanomolar biological activity range in fibroblast assays has made it tractable for concentration-response characterization. It should be noted that at supraphysiological copper concentrations, cell toxicity can occur, underscoring the importance of controlled dosing in any experimental design.
Published Research
The foundational collagen synthesis publication for GHK-Cu is Maquart, Pickart, Laurent, Gillery, Monboisse, and Borel, FEBS Letters, Vol. 238, No. 2 (1988), pp. 343–346: Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. This study demonstrated that GHK-Cu stimulated collagen synthesis in human skin fibroblast cultures at concentrations as low as 10⁻¹² M (1 picomolar), with maximal stimulation observed at approximately 10⁻⁹ M (1 nanomolar), at which concentration collagen synthesis was increased by roughly 80% relative to controls. This picomolar potency threshold was notable and has been cited extensively in subsequent literature. Additional matrix remodeling research is documented in Pickart, Gillery, and Maquart, Clinics in Dermatology, Vol. 17, No. 2 (1999), pp. 181–186, which examined collagen synthesis and matrix remodeling induced by copper peptides in the context of dermal wound repair. More recently, a 2026 review by Sarbaziha et al. published in Dermatological Reviews (Wiley, doi: 10.1002/der2.70067) evaluated copper peptides including GHK-Cu in the context of regenerative aesthetic dermatology, reflecting continued research interest. A 2018 analysis by Pickart and Margolina published in Cosmetics (MDPI) examined GHK-Cu’s proposed role in broad gene expression modulation, identifying upregulation of genes associated with tissue remodeling and downregulation of pathways associated with inflammation in computational analyses of public gene expression datasets.
Mechanism
Multiple distinct mechanisms have been proposed for GHK-Cu’s effects in cell culture and preclinical models, and the literature treats several of these as compatible rather than mutually exclusive. TGF-β pathway modulation is among the most commonly cited: GHK-Cu has been associated in cell culture studies with modulation of transforming growth factor-beta signaling, which regulates fibroblast proliferation and collagen gene expression. Specifically, studies have described effects on TGF-β1 receptor interactions and downstream SMAD pathway activation. Metalloproteinase regulation represents a second proposed mechanism: GHK-Cu has been studied in fibroblast cultures for effects on matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) expression, suggesting a possible role in balancing matrix synthesis and degradation — a balance critical to wound-healing and tissue remodeling research models. Copper delivery and superoxide dismutase activity constitute a third line of investigation: because Cu²⁺ is a required cofactor for the antioxidant enzyme copper-zinc superoxide dismutase (Cu/Zn-SOD), GHK-Cu has been hypothesized to serve as a bioavailable copper carrier in some cellular contexts, and studies have examined its association with SOD activity in fibroblast cultures. Gene expression modulation is supported by Pickart and Margolina’s computational analyses, which identified GHK-Cu as associated with shifts in expression patterns of genes relevant to collagen, fibronectin, and decorin production, as well as anti-inflammatory gene sets — though these findings are based on in silico correlation analyses and require experimental confirmation for each proposed gene target.
Supply Format
Struck Bio Labs supplies GHK-Cu in two research formats: a lyophilized powder in research-grade vials for researchers who require precise gravimetric dosing and custom formulation, and a serum-format preparation for investigators studying topical or transdermal delivery in preclinical models. Both formats are accompanied by lot-specific certificates of analysis verifying identity, purity, and copper-complex integrity. All materials are supplied for in vitro and preclinical research use only. For current specifications, lot availability, and CoA documentation, researchers should consult struckbiolabs.com.
FAQ
Who discovered GHK-Cu and when?
Loren Pickart first isolated the tripeptide GHK (glycyl-L-histidyl-L-lysine) from the alpha-2-macroglobulin fraction of human plasma albumin in 1973. His subsequent decades of research, much of it conducted in collaboration with French dermatology researchers including Maquart and colleagues, established the foundational published literature on GHK-Cu’s effects on fibroblast biology and extracellular matrix remodeling.
What was the key finding in the Maquart et al. 1988 FEBS Letters study?
The 1988 FEBS Letters study by Maquart, Pickart, and colleagues demonstrated that GHK-Cu stimulated collagen synthesis in human skin fibroblast cultures at concentrations as low as 1 picomolar (10⁻¹² M), with maximum stimulation of approximately 80% above controls at 1 nanomolar (10⁻⁹ M). This study is the primary published citation for GHK-Cu’s in vitro effects on collagen synthesis and is foundational to subsequent research in this area.
Is GHK-Cu found naturally in the human body?
Yes. GHK is an endogenous tripeptide identified in human plasma, with reported concentrations of approximately 200 ng/mL in younger adults. Plasma levels appear to decline with age based on reported measurements, and this age-related decline has been cited in the research literature as context for studying the molecule’s role in tissue repair biology, though a causal relationship between declining GHK levels and any specific biological outcome in humans has not been established.
What is the proposed role of copper in GHK-Cu’s mechanism?
The Cu²⁺ ion coordinated within the GHK complex has been proposed to serve multiple functions: facilitating cellular uptake through copper transporter systems, delivering bioavailable copper for metalloenzyme activity (particularly Cu/Zn-SOD), and modulating the affinity and activity of GHK at cellular receptor or extracellular matrix binding sites. The copper coordination chemistry is considered integral to the molecule’s observed biological activity, as GHK alone shows distinct and generally reduced activity relative to the copper complex in fibroblast assays.
What formats does Struck Bio Labs offer for GHK-Cu research?
Struck Bio Labs supplies GHK-Cu in two research formats: lyophilized powder vials for researchers requiring precise gravimetric reconstitution, and a serum-format preparation intended for preclinical topical or transdermal delivery investigations. Both are research-grade materials with lot-specific CoA documentation available at struckbiolabs.com and are not intended for any form of human use.
Are there any research limitations or caveats investigators should be aware of?
Yes, several caveats are important for research design. Much of the foundational in vitro research on GHK-Cu was conducted by Pickart’s own laboratory or by closely collaborating groups, and independent large-scale replication varies by endpoint. Copper toxicity is well-documented at supraphysiological concentrations, and researchers should design dose-response experiments with appropriate concentration ranges. Additionally, some mechanistic claims in secondary literature extrapolate from in silico gene expression analyses to claimed biological effects, which should be verified experimentally for each research context.
Who discovered GHK-Cu and when?
Loren Pickart first isolated the tripeptide GHK (glycyl-L-histidyl-L-lysine) from the alpha-2-macroglobulin fraction of human plasma albumin in 1973. His subsequent decades of research, much of it conducted in collaboration with French dermatology researchers including Maquart and colleagues, established the foundational published literature on GHK-Cu’s effects on fibroblast biology and extracellular matrix remodeling.
What was the key finding in the Maquart et al. 1988 FEBS Letters study?
The 1988 FEBS Letters study by Maquart, Pickart, and colleagues demonstrated that GHK-Cu stimulated collagen synthesis in human skin fibroblast cultures at concentrations as low as 1 picomolar (10⁻¹² M), with maximum stimulation of approximately 80% above controls at 1 nanomolar (10⁻⁹ M). This study is the primary published citation for GHK-Cu’s in vitro effects on collagen synthesis and is foundational to subsequent research in this area.
Is GHK-Cu found naturally in the human body?
Yes. GHK is an endogenous tripeptide identified in human plasma, with reported concentrations of approximately 200 ng/mL in younger adults. Plasma levels appear to decline with age based on reported measurements, and this age-related decline has been cited in the research literature as context for studying the molecule’s role in tissue repair biology, though a causal relationship between declining GHK levels and any specific biological outcome in humans has not been established.
What is the proposed role of copper in GHK-Cu’s mechanism?
The Cu²⁺ ion coordinated within the GHK complex has been proposed to serve multiple functions: facilitating cellular uptake through copper transporter systems, delivering bioavailable copper for metalloenzyme activity (particularly Cu/Zn-SOD), and modulating the affinity and activity of GHK at cellular receptor or extracellular matrix binding sites. The copper coordination chemistry is considered integral to the molecule’s observed biological activity, as GHK alone shows distinct and generally reduced activity relative to the copper complex in fibroblast assays.
What formats does Struck Bio Labs offer for GHK-Cu research?
Struck Bio Labs supplies GHK-Cu in two research formats: lyophilized powder vials for researchers requiring precise gravimetric reconstitution, and a serum-format preparation intended for preclinical topical or transdermal delivery investigations. Both are research-grade materials with lot-specific CoA documentation available at struckbiolabs.com and are not intended for any form of human use.
Are there any research limitations or caveats investigators should be aware of?
Yes, several caveats are important for research design. Much of the foundational in vitro research on GHK-Cu was conducted by Pickart’s own laboratory or by closely collaborating groups, and independent large-scale replication varies by endpoint. Copper toxicity is well-documented at supraphysiological concentrations, and researchers should design dose-response experiments with appropriate concentration ranges. Additionally, some mechanistic claims in secondary literature extrapolate from in silico gene expression analyses to claimed biological effects, which should be verified experimentally for each research context.
Further Reading: Purity & COA Testing • Storage Guide • What Are Research Peptides? • GHK-Cu – 100mg • Browse Healing Research Peptides • Disclaimer
The above content is provided for informational and educational purposes relating to scientific research only. It does not constitute medical advice, a personal health recommendation, or a treatment protocol. Struck Bio Labs products are supplied for laboratory research use only. They are not intended for human consumption, injection, or clinical use, and have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. See our full disclaimer at struckbiolabs.com/disclaimer/.